Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 120 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 M2DCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC0UW5SUUN3ME2wMlAxODJ6NzFOwG0> NEX6d4VUSU6JRWK=
LC-2-ad M3P0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37qTmlEPTB;MD6wNFA{OTdizszN NWHl[mZqW0GQR1XS
RL95-2 M2\Oemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W4XmlEPTB;MD6wNFA3PjhizszN M2HjTXNCVkeHUh?=
MZ1-PC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMECwO|I6KM7:TR?= NWLueFI6W0GQR1XS
TE-8 M2WzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDKSZJ3UUN3ME2wMlAxOTF5IN88US=> NFLq[2NUSU6JRWK=
SW954 NX[wUGpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DoSGlEPTB;MD6wNFEyQSEQvF2= M1v1WXNCVkeHUh?=
TE-11 M3PVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfTUWpFUUN3ME2wMlAxOTJ|IN88US=> M3zUOXNCVkeHUh?=
PSN1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnUeXpIUUN3ME2wMlAxOTNizszN NX\yV25mW0GQR1XS
MOLT-4 NVy5W2E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXkTWM2OD1yLkCwNVQ6KM7:TR?= MXjTRW5ITVJ?
697 M1PsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[ze2dKSzVyPUCuNFAyPSEQvF2= NXe0T2xkW0GQR1XS
ETK-1 NGT5[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMECxOVIh|ryP M3;1XHNCVkeHUh?=
TE-10 NHfnU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMECxOVQh|ryP NGjpV4JUSU6JRWK=
HUTU-80 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHsTWM2OD1yLkCwNVY5KM7:TR?= M{fH[HNCVkeHUh?=
NTERA-S-cl-D1 M{PGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvafYpZUUN3ME2wMlAxOjB7IN88US=> NWftPJpJW0GQR1XS
MFH-ino NIHCc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jwdWlEPTB;MD6wNFI3QCEQvF2= NUDuZYF[W0GQR1XS
IA-LM M2X0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMECyPEDPxE1? NXTKVY1OW0GQR1XS
MC116 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzHSXFKSzVyPUCuNFAzQDlizszN NGP5UXFUSU6JRWK=
RKO NXjJVlNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMECyPVgh|ryP MUXTRW5ITVJ?
MRK-nu-1 M3[xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLSTWM2OD1yLkCwNlk6KM7:TR?= NVrvUoFxW0GQR1XS
VA-ES-BJ NED6XGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXCbYVKSzVyPUCuNFA{KM7:TR?= NWTlNIdJW0GQR1XS
KALS-1 NWnBT5lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMECzNFgh|ryP MknwV2FPT0WU
BB30-HNC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT0dIx{UUN3ME2wMlAxOzF2IN88US=> MUfTRW5ITVJ?
ACN NVnEbG1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknxTWM2OD1yLkCwN|E3KM7:TR?= MmrOV2FPT0WU
TE-9 Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmniTWM2OD1yLkCwN|I3KM7:TR?= MkXHV2FPT0WU
SIG-M5 NVPUT4U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O0XmlEPTB;MD6wNFMzPyEQvF2= MYDTRW5ITVJ?
no-10 MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHiTWM2OD1yLkCwN|YzKM7:TR?= MmDqV2FPT0WU
EW-1 M2LlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u4fmlEPTB;MD6wNFM4OSEQvF2= MWHTRW5ITVJ?
SK-LMS-1 MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\vNWtKSzVyPUCuNFA1ODFizszN MlrrV2FPT0WU
GT3TKB MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PkW2lEPTB;MD6wNFQ{PCEQvF2= NVj0dXoyW0GQR1XS
ES4 M2OxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHwNI1KSzVyPUCuNFA1PDlizszN NIT5UIhUSU6JRWK=
IMR-5 NHH5VVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEC0OUDPxE1? MVfTRW5ITVJ?
NCI-H1648 NVrvW5JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rXSGlEPTB;MD6wNFQ3QSEQvF2= M{LscXNCVkeHUh?=
MV-4-11 Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV33clF6UUN3ME2wMlAxPDd3IN88US=> M{nWOHNCVkeHUh?=
SK-UT-1 NWmxTYlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOyTWM2OD1yLkCwOFgh|ryP MWPTRW5ITVJ?
NB13 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXWTWM2OD1yLkCwOFkyKM7:TR?= M1;IVXNCVkeHUh?=
DJM-1 M2PodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzydVg3UUN3ME2wMlAxPTNizszN M3j3b3NCVkeHUh?=
ES8 NV;GUnVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELZdlhKSzVyPUCuNFA2OzhizszN NFS0SlhUSU6JRWK=
TE-6 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMEC1O{DPxE1? NW\HTIxTW0GQR1XS
KS-1 MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHPbGpKSzVyPUCuNFA2QDJizszN M3TTNXNCVkeHUh?=
TE-1 NHLSUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LlVWlEPTB;MD6wNFYxPiEQvF2= NF64cHRUSU6JRWK=
ATN-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEC2NFkh|ryP NGDmcWVUSU6JRWK=
A4-Fuk M334[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\2N4FlUUN3ME2wMlAxPjFzIN88US=> MmnaV2FPT0WU
ALL-PO MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDmOFRKSzVyPUCuNFA3OyEQvF2= M4jR[3NCVkeHUh?=
BE-13 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD5TWM2OD1yLkCwOlM3KM7:TR?= MmrrV2FPT0WU
KM12 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rRTWlEPTB;MD6wNFY{PyEQvF2= M2nFUXNCVkeHUh?=
NOS-1 NXjoXWFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLJTWM2OD1yLkCwOlUh|ryP MmnqV2FPT0WU
SW962 MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrSS|VKSzVyPUCuNFA3PjJizszN NIDxTZlUSU6JRWK=
OCUB-M NXL0eXFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPLTWM2OD1yLkCwOlYzKM7:TR?= M{S0bHNCVkeHUh?=
NCI-H510A Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS0WoZUUUN3ME2wMlAxPjZ3IN88US=> NWPr[WZYW0GQR1XS
EW-16 MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjqPYhKSzVyPUCuNFA3QTRizszN MlXsV2FPT0WU
KGN MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;EbXVKSzVyPUCuNFA4OTJizszN NFHsNWFUSU6JRWK=
LS-411N MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMEC3NVch|ryP MVPTRW5ITVJ?
Becker NU\hUmJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGqzPIpKSzVyPUCuNFA4OiEQvF2= NYnvO5I1W0GQR1XS
HC-1 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMEC3NlEh|ryP MmrLV2FPT0WU
CESS NHPhWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP4XnVKSzVyPUCuNFA4OzdizszN MUjTRW5ITVJ?
KURAMOCHI NEX4W3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnziTWM2OD1yLkCwO|Q5KM7:TR?= M{Po[nNCVkeHUh?=
TGBC24TKB MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrXbldKSzVyPUCuNFA4PTJizszN NW\UdFNUW0GQR1XS
SW982 NUDLUZY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEC3OlYh|ryP NWXhd5E3W0GQR1XS
HCE-4 NHf5OotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnyTWM2OD1yLkCwO|Y4KM7:TR?= NIfKbIVUSU6JRWK=
LOUCY MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrLWZZKSzVyPUCuNFA4PzVizszN NHzTfnVUSU6JRWK=
8-MG-BA NXi1OXhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe5UJF1UUN3ME2wMlAxPzl4IN88US=> MV7TRW5ITVJ?
HT-144 MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvo[G9tUUN3ME2wMlAxQCEQvF2= M32wTHNCVkeHUh?=
LXF-289 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPSSHJKSzVyPUCuNFA5OThizszN NIfIO4NUSU6JRWK=
RS4-11 M2TFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rGOWlEPTB;MD6wNFg{PiEQvF2= MVfTRW5ITVJ?
DEL NGP2d|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HKbmlEPTB;MD6wNFg1PSEQvF2= NH;PVI1USU6JRWK=
OCI-AML2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLqNXhKSzVyPUCuNFA5PTJizszN NEmzUZBUSU6JRWK=
CCRF-CEM MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS2TWM2OD1yLkCwPFcyKM7:TR?= M1KyXnNCVkeHUh?=
A388 M1nvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMEC4O|Qh|ryP M2nWW3NCVkeHUh?=
KNS-42 M1rhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnqPVBKSzVyPUCuNFA5QTFizszN MmXuV2FPT0WU
OVCAR-4 M3rJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{GwdWlEPTB;MD6wNFkxPCEQvF2= Mm\0V2FPT0WU
NCI-H1355 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPkTWM2OD1yLkCwPVE1KM7:TR?= NIizNmRUSU6JRWK=
BL-70 NV3PbZNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPHNGpKSzVyPUCuNFA6OyEQvF2= NVPXZXJkW0GQR1XS
BL-41 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e0b2lEPTB;MD6wNFk{PCEQvF2= MoiyV2FPT0WU
A101D NU\ORWFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi0TWM2OD1yLkCwPVYh|ryP NFjjRnNUSU6JRWK=
HL-60 MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli4TWM2OD1yLkCwPVY3KM7:TR?= NUjsc49[W0GQR1XS
COR-L279 M4S4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rFbGlEPTB;MD6wNFk6QSEQvF2= M{O2UHNCVkeHUh?=
NCI-SNU-16 MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHuxS2xKSzVyPUCuNFExODhizszN MlrVV2FPT0WU
Calu-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXaWWRFUUN3ME2wMlAyODF{IN88US=> MVvTRW5ITVJ?
SR Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3pcHFyUUN3ME2wMlAyODJ4IN88US=> MX3TRW5ITVJ?
QIMR-WIL MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP6SppKUUN3ME2wMlAyODN|IN88US=> MmrSV2FPT0WU
LB647-SCLC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMEGwOVEh|ryP NFrxdZVUSU6JRWK=
RPMI-8226 NWi1SWxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\KVHdKSzVyPUCuNFEyODJizszN NH[0fJhUSU6JRWK=
SK-PN-DW M1LTXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C3eWlEPTB;MD6wNVEyOiEQvF2= NVfBZ4NHW0GQR1XS
SF268 MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHNZ3FqUUN3ME2wMlAyOTVzIN88US=> MW\TRW5ITVJ?
HD-MY-Z MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jqSWlEPTB;MD6wNVE3OyEQvF2= MnPqV2FPT0WU
DOHH-2 M{C3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLjcFZGUUN3ME2wMlAyOjB|IN88US=> NV\TWFduW0GQR1XS
SCC-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\keGhKSzVyPUCuNFEzODRizszN MVjTRW5ITVJ?
ST486 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEGyNFQh|ryP M{jL[3NCVkeHUh?=
NALM-6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\DWHpXUUN3ME2wMlAyOjF2IN88US=> M2Hm[nNCVkeHUh?=
NCI-H1436 NWXsUpdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLUc4ZzUUN3ME2wMlAyOjNzIN88US=> MXnTRW5ITVJ?
KE-37 NHfxN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fLRWlEPTB;MD6wNVI{PCEQvF2= Mn3vV2FPT0WU
RPMI-8402 NIDpeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrjb3cxUUN3ME2wMlAyOjV4IN88US=> NYDWVJgxW0GQR1XS
RXF393 M1LPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqxTWM2OD1yLkCxNlU4KM7:TR?= MoT4V2FPT0WU
KARPAS-45 MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[yfHRKSzVyPUCuNFEzPyEQvF2= NF[5R4hUSU6JRWK=
HOP-62 NGfOeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPkSJRKSzVyPUCuNFEzPzZizszN NG\zN3JUSU6JRWK=
ES1 M3e2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\mcG9KSzVyPUCuNFEzQDhizszN MXHTRW5ITVJ?
L-363 NEXHUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfXO|ZKSzVyPUCuNFE{PTFizszN MVzTRW5ITVJ?
GI-1 M{f2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEGzO|Mh|ryP NEXIVFdUSU6JRWK=
CTV-1 M4XlNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\E[2lEPTB;MD6wNVQ4QCEQvF2= NUjHV3dtW0GQR1XS
TE-5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEG0PVYh|ryP MorOV2FPT0WU
SNU-C2B MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS4VWU4UUN3ME2wMlAyPDl4IN88US=> MkPBV2FPT0WU
K-562 NX;ofY9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jFU2lEPTB;MD6wNVUyPiEQvF2= NH3NZ3dUSU6JRWK=
SNB75 NWfSXoQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMEG1OEDPxE1? NEX0OVFUSU6JRWK=
MOLT-13 Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7hdVZyUUN3ME2wMlAyPjN5IN88US=> M3XwN3NCVkeHUh?=
LS-123 NWPPbopiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XndGlEPTB;MD6wNVY3PCEQvF2= NWPnZ4VzW0GQR1XS
NCI-SNU-5 NUi4dIFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEG3NFEh|ryP MV;TRW5ITVJ?
Daudi MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P5[GlEPTB;MD6wNVcxQCEQvF2= MVnTRW5ITVJ?
A253 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ntemlEPTB;MD6wNVc{QCEQvF2= MojlV2FPT0WU
TGBC1TKB M2rzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfV[5N6UUN3ME2wMlAyPzV{IN88US=> Mm\oV2FPT0WU
SJSA-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEG3Olch|ryP MnzrV2FPT0WU
NCCIT M1\ncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfXS5NKSzVyPUCuNFE4PjlizszN M3jLXHNCVkeHUh?=
NCI-H69 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTZbHNKSzVyPUCuNFE4PzhizszN M3vkc3NCVkeHUh?=
SH-4 NEjUb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3WcGs{UUN3ME2wMlAyQDl3IN88US=> NGTFW5BUSU6JRWK=
HCC1187 M1TKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ycmlEPTB;MD6wNVkzPCEQvF2= MlvkV2FPT0WU
HCC1599 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO0clNKSzVyPUCuNFIxOiEQvF2= NVz5fXJ{W0GQR1XS
ONS-76 NF[xXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMEKwN|Yh|ryP M3XVcHNCVkeHUh?=
KU812 NXfoO4JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7Pe4VKSzVyPUCuNFIxOzlizszN MYnTRW5ITVJ?
ML-2 M3ThUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnyTWM2OD1yLkCyNFQ4KM7:TR?= MmOxV2FPT0WU
HCE-T MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fYbmlEPTB;MD6wNlA6OiEQvF2= M4fXSXNCVkeHUh?=
NCI-H446 NVftcVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvUdVhmUUN3ME2wMlAzOTF{IN88US=> MoH2V2FPT0WU
RPMI-6666 M4f2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDuUnVKSzVyPUCuNFIyPDlizszN NUT4PXl[W0GQR1XS
MOLT-16 NXrQ[Y84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TqVmlEPTB;MD6wNlE2OyEQvF2= NXjtfokzW0GQR1XS
JiyoyeP-2003 MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMEKxO|Yh|ryP NEDIbZFUSU6JRWK=
MHH-PREB-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ixVWlEPTB;MD6wNlE6OSEQvF2= M3nsbnNCVkeHUh?=
MC-CAR M2\mO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfPdG9KSzVyPUCuNFI{OjZizszN NIrFRodUSU6JRWK=
BC-3 NH7uRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEKzOFQh|ryP M161ZnNCVkeHUh?=
KINGS-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS0TWM2OD1yLkCyN|U2KM7:TR?= NEjwcZJUSU6JRWK=
PF-382 Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2zTWM2OD1yLkCyN|c5KM7:TR?= M4fXbHNCVkeHUh?=
J-RT3-T3-5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[2TWM2OD1yLkCyN|g{KM7:TR?= MUHTRW5ITVJ?
SF539 NYHoUWQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHZc4VnUUN3ME2wMlAzPDBzIN88US=> MVPTRW5ITVJ?
LB831-BLC NI\SVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILVdXhKSzVyPUCuNFI1QDVizszN M1TKRnNCVkeHUh?=
DMS-114 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL4b2xKUUN3ME2wMlAzPTB{IN88US=> MnH2V2FPT0WU
LB1047-RCC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfPTWM2OD1yLkCyOVEh|ryP MnLiV2FPT0WU
LB771-HNC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ziNGlEPTB;MD6wNlU{PCEQvF2= MWfTRW5ITVJ?
BB65-RCC NX3F[5pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrlcYdKSzVyPUCuNFI2OzRizszN NWrwUFdqW0GQR1XS
BV-173 MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rPemlEPTB;MD6wNlU2PCEQvF2= NFOxbHJUSU6JRWK=
ARH-77 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPjTWM2OD1yLkCyOlAyKM7:TR?= M1voWHNCVkeHUh?=
IST-MEL1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fTUGlEPTB;MD6wNlYzOyEQvF2= MULTRW5ITVJ?
NB1 MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUKzS4ZsUUN3ME2wMlAzPjh5IN88US=> MofrV2FPT0WU
EoL-1-cell NF;kXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3RTWM2OD1yLkCyOlg5KM7:TR?= MYfTRW5ITVJ?
KY821 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofvTWM2OD1yLkCyOlk4KM7:TR?= M2fobnNCVkeHUh?=
CMK NVu3eopST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nEemlEPTB;MD6wNlc{PCEQvF2= NU\xdI9lW0GQR1XS
NCI-H2126 MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMEK3Olgh|ryP M2nBZ3NCVkeHUh?=
NCI-H526 NVO1ZnFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTJUllmUUN3ME2wMlAzQDlzIN88US=> MXTTRW5ITVJ?
COLO-684 M2P5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nDUWlEPTB;MD6wNlkxQCEQvF2= NUDzR3FsW0GQR1XS
NCI-H747 NGD6Z|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\UOFhKSzVyPUCuNFI6OzNizszN MV3TRW5ITVJ?
JAR M4PnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fIfmlEPTB;MD6wNlk1PiEQvF2= MX3TRW5ITVJ?
MEG-01 MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMEK5O|gh|ryP M176dHNCVkeHUh?=
MONO-MAC-6 NGf4eotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLKSJJKSzVyPUCuNFMxOjNizszN MmnyV2FPT0WU
IST-SL1 MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjXTWM2OD1yLkCzNFQzKM7:TR?= NYX0[2JnW0GQR1XS
CPC-N NH3SenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPMPWRKSzVyPUCuNFMxPzlizszN M3rnNXNCVkeHUh?=
NCI-H1963 NVXYd5l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHZTWM2OD1yLkCzNVMyKM7:TR?= M{PPO3NCVkeHUh?=
K052 MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn6S2V2UUN3ME2wMlA{OjR5IN88US=> MV\TRW5ITVJ?
KM-H2 M3[4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMEOzNFch|ryP M2G4ZXNCVkeHUh?=
TE-12 NFLrZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzIZoYyUUN3ME2wMlA{OzB7IN88US=> NUK1b4xUW0GQR1XS
TK10 M2K1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHDTWM2OD1yLkCzN|U3KM7:TR?= Mn[xV2FPT0WU
NMC-G1 NU\iRZZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLJTWM2OD1yLkCzOFUzKM7:TR?= M2PiO3NCVkeHUh?=
no-11 M1HzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT6TWM2OD1yLkCzOFc5KM7:TR?= M2CwUXNCVkeHUh?=
NCI-H524 M13vUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTZTWM2OD1yLkCzOVI6KM7:TR?= M4nFbnNCVkeHUh?=
MHH-CALL-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUSxSWVyUUN3ME2wMlA{PTZ{IN88US=> MX7TRW5ITVJ?
GB-1 NWCzNG53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMEO2JO69VQ>? NYey[YEyW0GQR1XS
OPM-2 NH7rVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\DS4dyUUN3ME2wMlA{Pjd|IN88US=> MkHMV2FPT0WU
RH-1 NEfu[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\xTWM2OD1yLkCzPFE6KM7:TR?= M3O2UnNCVkeHUh?=
NCI-H64 NH7w[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLLTWM2OD1yLkCzPFU4KM7:TR?= M4XtUXNCVkeHUh?=
EVSA-T M3qyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMEO5NlMh|ryP M4DvPHNCVkeHUh?=
KARPAS-299 NEX2TnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33Jd2lEPTB;MD6wN|k5KM7:TR?= M3XvfXNCVkeHUh?=
MZ7-mel MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DwN2lEPTB;MD6wOFA1KM7:TR?= NX7sOlBIW0GQR1XS
LB373-MEL-D M4nucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMESxNFUh|ryP NGm4NWJUSU6JRWK=
HEL NIjweFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTkTWM2OD1yLkC0NVQh|ryP MmP1V2FPT0WU
SW872 NWS2XXBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLBOohlUUN3ME2wMlA1OjFizszN MWHTRW5ITVJ?
DU-4475 MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;TfZNKSzVyPUCuNFQzPDRizszN NYDUSGRJW0GQR1XS
IST-SL2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzBXVRKSzVyPUCuNFQzPzVizszN M37nTnNCVkeHUh?=
NCI-H82 Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fYZWlEPTB;MD6wOFMxPyEQvF2= NGfHWXBUSU6JRWK=
LC4-1 NEn6[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMESzOVEh|ryP NXX5bYtxW0GQR1XS
HDLM-2 NW\Hd5pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG3TWM2OD1yLkC0N|kzKM7:TR?= NYXweIx2W0GQR1XS
MMAC-SF MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULwToR6UUN3ME2wMlA1PTN2IN88US=> M4HsNnNCVkeHUh?=
L-540 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PIfGlEPTB;MD6wOFY{QSEQvF2= M17H[3NCVkeHUh?=
MZ2-MEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLQfoxMUUN3ME2wMlA1PzR{IN88US=> MXHTRW5ITVJ?
LU-134-A Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XrOGlEPTB;MD6wOFc4OyEQvF2= MULTRW5ITVJ?
UACC-257 NWm2cWt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH1TWM2OD1yLkC0PFQ6KM7:TR?= M{TacXNCVkeHUh?=
NCI-H1581 NUjuVYFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m1dWlEPTB;MD6wOFk2OyEQvF2= NH\VVFdUSU6JRWK=
NB17 M2nHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXZVmMyUUN3ME2wMlA1QTd7IN88US=> M{PhO3NCVkeHUh?=
SBC-1 M3W1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHvbZZKSzVyPUCuNFUxPDJizszN NFnMd2FUSU6JRWK=
TALL-1 M3rhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7PUmJKSzVyPUCuNFUxPDVizszN M4iyWnNCVkeHUh?=
NCI-H1304 Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnXTWM2OD1yLkC1NlA5KM7:TR?= M17INnNCVkeHUh?=
NEC8 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jsbmlEPTB;MD6wOVI5PiEQvF2= MUjTRW5ITVJ?
CAL-148 NG\wS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfGZoZKSzVyPUCuNFU1OzlizszN MkDIV2FPT0WU
CGTH-W-1 M4PYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HFZWlEPTB;MD6wOVQ1QSEQvF2= NFPnfo1USU6JRWK=
NCI-H889 M{P5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjTTWM2OD1yLkC1OVkzKM7:TR?= NEftOo9USU6JRWK=
GR-ST NHXz[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PUNWlEPTB;MD6wOVYzOSEQvF2= NIXtPYdUSU6JRWK=
KARPAS-422 NGCybGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLHTYNKSzVyPUCuNFU3PSEQvF2= MX;TRW5ITVJ?
RPMI-8866 Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnKd3A3UUN3ME2wMlA2PzF{IN88US=> M3fj[HNCVkeHUh?=
SCLC-21H M2Hrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP6TWM2OD1yLkC1PFg1KM7:TR?= NFnvbYpUSU6JRWK=
COR-L88 M3\IUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P4c2lEPTB;MD6wOVkzPyEQvF2= M2[3SHNCVkeHUh?=
LU-139 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO2eGVKSzVyPUCuNFU6QDZizszN MmL3V2FPT0WU
SF126 NETaVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i3eGlEPTB;MD6wOlE{OyEQvF2= NYPiVms3W0GQR1XS
NCI-H1882 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnxNoJKSzVyPUCuNFY1OjRizszN NGH3eYdUSU6JRWK=
EW-24 MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PwdGlEPTB;MD6wOlQ5OyEQvF2= M37zUnNCVkeHUh?=
CP67-MEL NXPM[XZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwME[4NUDPxE1? NGPSSYVUSU6JRWK=
DG-75 NH\jS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\SeIh2UUN3ME2wMlA3QDl7IN88US=> MYDTRW5ITVJ?
LOXIMVI NYTYR4V5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjMTWM2OD1yLkC3NFI5KM7:TR?= NGq0[YFUSU6JRWK=
HH MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnPTWM2OD1yLkC3NVU4KM7:TR?= NELrfXNUSU6JRWK=
K5 M33KR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rQXGlEPTB;MD6wO|IzPiEQvF2= M{\RW3NCVkeHUh?=
EC-GI-10 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\abZM6UUN3ME2wMlA4OjV5IN88US=> NXP6ZlV1W0GQR1XS
SK-N-DZ NVP5RlVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn1RZZKSzVyPUCuNFc{ODdizszN MYrTRW5ITVJ?
A3-KAW NH7UO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XsOWlEPTB;MD6wO|M2OSEQvF2= Mlz0V2FPT0WU
MLMA NX75T2J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMEe0OlUh|ryP Mmj2V2FPT0WU
LB996-RCC MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfETWM2OD1yLkC3O|A4KM7:TR?= NXjMNZRTW0GQR1XS
OS-RC-2 Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH0WZBtUUN3ME2wMlA4PzR6IN88US=> M4m0eHNCVkeHUh?=
CTB-1 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLYZo1DUUN3ME2wMlA4QDFizszN M3vXWXNCVkeHUh?=
IST-MES1 NVvncFZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMEe5NVIh|ryP NYe2UnFVW0GQR1XS
LS-1034 NX[wO3pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrVTWM2OD1yLkC4NFM2KM7:TR?= MlvCV2FPT0WU
HT NEXE[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XDN2lEPTB;MD6wPFA5PiEQvF2= NFS0VGdUSU6JRWK=
NCI-H2141 NYLhXYRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL5Z3RKSzVyPUCuNFgyKM7:TR?= M1PyU3NCVkeHUh?=
LB2518-MEL NUDFW|dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrhTWM2OD1yLkC4NVQyKM7:TR?= M2XiSnNCVkeHUh?=
GI-ME-N MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofCTWM2OD1yLkC4OFUzKM7:TR?= M17FN3NCVkeHUh?=
TGW MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMEi2NFch|ryP MW\TRW5ITVJ?
SK-NEP-1 M{TpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfDTWM2OD1yLkC4OlQyKM7:TR?= NIHtbVVUSU6JRWK=
NOMO-1 NF63ToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT1TWM2OD1yLkC5Nlc2KM7:TR?= NYroSYR[W0GQR1XS
ES6 M37qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnPTWM2OD1yLkC5OVg6KM7:TR?= NETtSlNUSU6JRWK=
NCI-H209 M3;hVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPVTWM2OD1yLkC5O|g3KM7:TR?= M2DG[XNCVkeHUh?=
GAK NWn4N5hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHjXYdKSzVyPUCuNVAyPiEQvF2= NGO4c5FUSU6JRWK=
BC-1 M2j4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Lwe2lEPTB;MD6xNFM3OSEQvF2= NHj2Z49USU6JRWK=
KLE MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nyd2lEPTB;MD6xNFQ1OyEQvF2= M1nNVXNCVkeHUh?=
EW-3 NGG4ZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrhSWlbUUN3ME2wMlExQThizszN M{D1SXNCVkeHUh?=
NKM-1 M1X6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMUGxJO69VQ>? NYDhRpZyW0GQR1XS
D-336MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTI[nBKSzVyPUCuNVEzPDRizszN M3Tu[HNCVkeHUh?=
NB69 M3u4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\NWmlEPTB;MD6xNVMxOSEQvF2= M1T1WXNCVkeHUh?=
D-263MG NYOyZ|I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nHVWlEPTB;MD6xNVcyOiEQvF2= MkS4V2FPT0WU
KP-N-YS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PZXGlEPTB;MD6xNlI6OSEQvF2= MWTTRW5ITVJ?
NCI-H1155 M{joUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMUK1OVgh|ryP MXLTRW5ITVJ?
BOKU M1TNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH2wSohKSzVyPUCuNVI2PzlizszN MmL4V2FPT0WU
LAMA-84 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnQN3VyUUN3ME2wMlEzQTlizszN M3j0WXNCVkeHUh?=
Raji MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHPVJBKSzVyPUCuNVMyOTdizszN NX;vZW1IW0GQR1XS
LU-65 NFq1epNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PZWGlEPTB;MD6xN|MxPyEQvF2= NWPDeJlMW0GQR1XS
NCI-H187 MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uzdmlEPTB;MD6xN|kzPCEQvF2= M3jESXNCVkeHUh?=
GCIY MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnPfJM4UUN3ME2wMlE1QTBzIN88US=> NWTqWZZRW0GQR1XS
NCI-H2107 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHKxW4JKSzVyPUCuNVUxQCEQvF2= NYLYXFY1W0GQR1XS
NCI-H1522 MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMUWyOlYh|ryP M{\q[HNCVkeHUh?=
NB6 M4\GfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTUb|hoUUN3ME2wMlE2PjJ|IN88US=> M1zwZXNCVkeHUh?=
EM-2 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrqc3FKSzVyPUCuNVU4ODZizszN MoTzV2FPT0WU
HCC2218 M4DaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVOyRmVqUUN3ME2wMlE2QThizszN MnizV2FPT0WU
NCI-H748 M1m2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTDTWM2OD1yLkG2N|c3KM7:TR?= NUjZR2FqW0GQR1XS
MS-1 NYW3OHU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LDc2lEPTB;MD6xOlU{PyEQvF2= NYnNeoV7W0GQR1XS
NB5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlKwTWM2OD1yLkG2OVk4KM7:TR?= NH3LVFlUSU6JRWK=
OMC-1 NGLXVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHqb3JwUUN3ME2wMlE3Pjh6IN88US=> NIqxZWpUSU6JRWK=
NCI-H345 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrKTWM2OD1yLkG2PVI5KM7:TR?= M3;URnNCVkeHUh?=
L-428 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\NeWhKUUN3ME2wMlE3QTR3IN88US=> M2TUVHNCVkeHUh?=
SCH M3foXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvhUlFmUUN3ME2wMlE5Pjh3IN88US=> NIXaOGxUSU6JRWK=
NCI-H1417 NF3YR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfufpdKSzVyPUCuNVkzOjdizszN MkDTV2FPT0WU
COLO-320-HSR NVK2fYRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnNWJJFUUN3ME2wMlE6PTN{IN88US=> NEHWWJRUSU6JRWK=
BT-474 M{TVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7ETWM2OD1yLkKwPFkzKM7:TR?= NXmxZmVkW0GQR1XS
GDM-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXxZWI3UUN3ME2wMlIyQTdzIN88US=> MkH6V2FPT0WU
NCI-H2196 M3zZTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFqyWIpKSzVyPUCuNlIzOzVizszN NH3VPGdUSU6JRWK=
KP-N-RT-BM-1 Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\Cfm5KSzVyPUCuNlI{PDlizszN M1vtS3NCVkeHUh?=
KNS-81-FD MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HN[WlEPTB;MD6yNlk2QCEQvF2= NHPDeJFUSU6JRWK=
COLO-668 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLoVnc3UUN3ME2wMlI{Pjd3IN88US=> Mnr0V2FPT0WU
C2BBe1 NUTwUpQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHMTWM2OD1yLkK2O|Q4KM7:TR?= NHjvN4VUSU6JRWK=
Ramos-2G6-4C10 NGrhb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf4SmlKSzVyPUCuNlY6PTRizszN M1\0VHNCVkeHUh?=
CAS-1 MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;HZWlEPTB;MD6yO|A6PiEQvF2= NIfkeopUSU6JRWK=
GOTO MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvCTWM2OD1yLkK3PFk1KM7:TR?= NHzxVIdUSU6JRWK=
LP-1 NHW0RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPK[JRKSzVyPUCuNlgxPTdizszN NWPOZYcxW0GQR1XS
NCI-SNU-1 MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTwXGRPUUN3ME2wMlI6PDJ{IN88US=> MWnTRW5ITVJ?
EB-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVznNGlwUUN3ME2wMlI6QTd7IN88US=> NIPvfXBUSU6JRWK=
MHH-NB-11 NGe0dY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLSTJFKSzVyPUCuN|A1ODJizszN MoHTV2FPT0WU
SK-N-FI NIracG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P0SWlEPTB;MD6zNVY6OiEQvF2= NGTBZldUSU6JRWK=
HCC2157 NUjLXXl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;3PFhDUUN3ME2wMlM{QTF|IN88US=> NUm2[phwW0GQR1XS
SIMA M2jUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwM{S1PFEh|ryP MVTTRW5ITVJ?
MDA-MB-134-VI MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3O[nBSUUN3ME2wMlM3QTJ6IN88US=> NH\lbGVUSU6JRWK=
NCI-H1694 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17FWGlEPTB;MD6zO{DPxE1? NIG0O4RUSU6JRWK=
EHEB MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL0TWM2OD1yLkO5NFg2KM7:TR?= MmPKV2FPT0WU
U-266 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwM{m4OFYh|ryP MX7TRW5ITVJ?
LC-1F Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r4fWlEPTB;MD60N|c3PSEQvF2= MWHTRW5ITVJ?
SHP-77 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O3WWlEPTB;MD60O|g2PSEQvF2= MVHTRW5ITVJ?
LS-513 NEfiWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHE[5hKSzVyPUCuOFk{ODdizszN M4XDOHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK; 

PubMed: 20068074     


Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells.

MARCKS (pSer159/163); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

Src (pTyr416); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; 

PubMed: 29849942     


OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot.

Id1; 

PubMed: 25344919     


(A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner.

MARCKS; 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

20068074 26015406 29849942 25344919
Growth inhibition assay
Cell viability; 

PubMed: 28823711     


Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.

28823711
Immunofluorescence
α-tubulin; 

PubMed: 22904633     


Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel.

Rab11a/BV9; 

PubMed: 29290815     


Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).

22904633 29290815
In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[4]

- Collapse
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04000906 Not yet recruiting Drug: NAB paclitaxel|Drug: Cisplatin Peritoneal Carcinomatosis University Hospital Geneva September 2019 Phase 1
NCT04046887 Not yet recruiting Drug: Lonsurf|Drug: Gemcitabine|Drug: Nab-Paclitaxel Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma Patrick Joseph Loehrer Sr.|Indiana University|Taiho Oncology Inc. August 2019 Phase 1
NCT03779464 Recruiting Drug: S1 or Gemcitabine Pancreatic Cancer|Nab-paclitaxel|Gemcitabine|S1 Wuhan Union Hospital China August 1 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID